In essence, this study suggests that PTX3, a potential biomarker for distinguishing prostate cancer from BPH, promotes tumor progression by inhibiting the activation of the terminal complement pathway through increased CD59 expression (75). This evidence concerns the gene CD59 and prostate carcinoma.